Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sarcoma.

R Maki1

  • 1Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6007, USA. makir@mskcc.org

The Oncologist
|August 29, 2001
PubMed
Summary
This summary is machine-generated.

New systemic therapies show promise for sarcoma treatment. Imatinib mesylate, ecteinascidin-743, and gemcitabine-based regimens offer hope for effective sarcoma treatment options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report.

ESMO open·2024
Same author

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.

British journal of cancer·2013
Same author

How a multidisciplinary team improved a process to attain positive patient outcome.

Insight (American Society of Ophthalmic Registered Nurses)·2002
Same author

Genetic determinants of bone mineral content in premature infants.

Archives of disease in childhood. Fetal and neonatal edition·2001
Same author

Enamel defects in primary and permanent teeth of children born prematurely.

Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·2000
Same journal

Target trial emulation studies in oncology: a comprehensive analysis.

The oncologist·2026
Same journal

Durable Response to Sotorasib in KRAS G12C-Mutant Intrahepatic Cholangiocarcinoma: A Case Report.

The oncologist·2026
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sarcomas remain challenging to treat with limited effective systemic therapies.
  • The development of novel targeted agents is crucial for improving patient outcomes.

Purpose of the Study:

  • To review innovative systemic therapies for sarcomas presented at ASCO 2001.
  • To highlight agents showing significant activity in preclinical and clinical studies.

Main Methods:

  • Review of data presented at ASCO 2001.
  • Focus on systemic agents including imatinib mesylate, ecteinascidin-743, and gemcitabine.

Main Results:

  • Imatinib mesylate (STI571, Gleevec) demonstrated activity in chronic myelogenous leukemia and gastrointestinal stromal tumors.
  • Ecteinascidin-743 (ET-743) showed activity in a subset of soft-tissue sarcomas.

Related Experiment Videos

  • Gemcitabine-based regimens exhibited activity against certain soft-tissue sarcomas.

    • Conclusions:

    • The emergence of imatinib mesylate, ET-743, and gemcitabine offers new hope for effective sarcoma systemic therapy.
    • These findings suggest a potential paradigm shift in sarcoma treatment strategies.